Intellia Therapeutics Inc
NTLA
Market Cap$2.4B
Close$
$-4.64
117.7% downside
Current Fair Value
117.7% downsideOvervalued by 117.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.40 Billion |
|---|---|
| Enterprise Value | $1.49 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-5.42 |
| Beta | 2.09 |
| Outstanding Shares | 96,438,608 |
| Avg 30 Day Volume | 1,274,103 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.98 |
|---|---|
| PEG | -30.13 |
| Price to Sales | - |
| Price to Book Ratio | 2.62 |
| Enterprise Value to Revenue | 40.94 |
| Enterprise Value to EBIT | -2.8 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Intellia Therapeutics Inc
211 employees
CEO: John Leonard Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...